

Patient Alert Card

- important safety information

▼ **XELJANZ[®]**
(tofacitinib)



▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get, see www.legemiddelverket.no/pasientmelding

- This card contains important safety information that you need to be aware of before you start taking Xeljanz and during your treatment with Xeljanz. If you are unsure of this information, please ask your doctor/pharmacist to explain it to you.
- Keep this card with you and show it to any health care personnel involved in your care.
- For more information, please refer to the Xeljanz package leaflet in the pack or at www.felleskatalogen.no. Use Xeljanz as described in the package leaflet, unless your doctor has told you otherwise.

Tell your doctor and pharmacist about ALL the medicines you are taking, including prescription and non-prescription medicines, vitamins and herbal supplements.

Xeljanz is not recommended for use with biologic medicines for the treatment of rheumatoid arthritis, psoriatic arthritis or ulcerative colitis. Nor is Xeljanz recommended for use with certain other medicines that depress your immune system (for instance azathioprine, mercaptopurine, tacrolimus or cyclosporine). Taking Xeljanz with these medicines may increase your risk of immunosuppression and infection.

Other information (please fill in):

Patient: _____

Doctor: _____

Doctor's phone: _____

If you stop taking Xeljanz, you should keep this card with you for at least 2 months after taking the last dose. Date: _____

Pfizer Norge AS, Postboks 3, 1324 Lysaker
Tel: 67 52 61 00, www.pfizer.no

During treatment with Xeljanz

Tell your doctor immediately if you:

- Develop symptoms of an infection, such as fever, persistent cough, weight loss, or excessive tiredness. Xeljanz may increase your risk of getting infections, which can become serious if not treated. You may be at a higher risk for infections if you are 65 years of age or older, if you have diabetes or chronic lung disease, or if you use corticosteroids. Your Xeljanz treatment may be stopped by your doctor.
- Develop any symptoms of shingles (herpes zoster), such as painful skin rash or blisters.

- Have been in close contact with a person with tuberculosis.
- Develop shortness of breath or breathing problems. These may be symptoms of interstitial lung disease.
- Develop signs and symptoms of abdominal problems, such as stomach pain, abdominal pain, blood in your stool, or any change in your bowel habits combined with fever.
- Notice any new growth on the skin, or if you notice any changes in existing moles or spots.
- Develop yellow skin, nausea or vomiting.

- Plan to have a vaccine. Certain vaccines should not be taken while using Xeljanz.
- Become pregnant or plan on becoming pregnant. Do not use Xeljanz during pregnancy. If you are a woman of childbearing age, you should use effective contraception during treatment with Xeljanz and for at least 4 weeks after the last dose.
- Are breastfeeding. Do not breastfeed while you are being treated with Xeljanz.

Important information for health care personnel:

The carrier of this card uses Xeljanz. It is important to take this into consideration with all treatment.

For more information than what is given in this card, please see the product information (preparatomtale, SPC) found at www.legemiddelsok.no